Drug intelligence / Profile preview

Omnitrenidol

Development stage
Unknown
Lead developer
IT3 Medical
Modality
Small Molecules
Administration
Intraarticular, Intramuscular, Percutaneous
01

Overview

**Omnitrenidol** is a prescription injection-system kit containing the small-molecule local anesthetic **lidocaine hydrochloride** and the synthetic corticosteroid **triamcinolone acetonide**. Lidocaine blocks voltage-gated sodium-channel-mediated neuronal impulse conduction to produce local or regional anesthesia, while triamcinolone acetonide activates glucocorticoid receptors to suppress inflammatory signaling. The kit is intended for procedural local anesthesia and corticosteroid injection use, including infiltration and nerve-block-related administration routes. The FDA label identifies IT3 Medical as the product packager and lists the product as an abbreviated new drug application product. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e31a76e5-719c-4b4d-8bda-5af71a3e377b))

Brand names
Omnitrenidol
Other names
lidocaine hydrochloride + triamcinolone acetonideOmnitrenidol Injection System
02

Targets

GR (Glucocorticoid receptor)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Omnitrenidol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omnitrenidol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call